Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)

Sanjay Popat; Myung Ju Ahn; Simon Ekman; Natasha B. Leighl; Suresh S. Ramalingam; Thanyanan Reungwetwattana; Shankar Siva; Masahiro Tsuboi; Yi Long Wu; James Chih Hsin Yang

doi:10.1007/s11523-023-00947-9

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)

Sanjay Popat, Myung Ju Ahn, Simon Ekman, Natasha B. Leighl, Suresh S. Ramalingam, Thanyanan Reungwetwattana, Shankar Siva, Masahiro Tsuboi, Yi Long Wu, James Chih Hsin Yang

Research output: Contribution to journal › Comment/debate

Abstract

While typesetting the articles the formatting of the Tables was incorrect. Now this has been corrected. The original article has been corrected.

Original language	English
Pages (from-to)	311
Number of pages	1
Journal	Targeted Oncology
Volume	18
Issue number	2
DOIs	https://doi.org/10.1007/s11523-023-00947-9
State	Published - Mar 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11523-023-00947-9

Fingerprint

Dive into the research topics of 'Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)'. Together they form a unique fingerprint.

Cite this

Popat, S., Ahn, M. J., Ekman, S., Leighl, N. B., Ramalingam, S. S., Reungwetwattana, T., Siva, S., Tsuboi, M., Wu, Y. L., & Yang, J. C. H. (2023). Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7). Targeted Oncology, 18(2), 311. https://doi.org/10.1007/s11523-023-00947-9

@article{94d428f784c547608d8bc536d1ea1abd,

title = "Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)",

abstract = "While typesetting the articles the formatting of the Tables was incorrect. Now this has been corrected. The original article has been corrected.",

author = "Sanjay Popat and Ahn, \{Myung Ju\} and Simon Ekman and Leighl, \{Natasha B.\} and Ramalingam, \{Suresh S.\} and Thanyanan Reungwetwattana and Shankar Siva and Masahiro Tsuboi and Wu, \{Yi Long\} and Yang, \{James Chih Hsin\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2023.",

year = "2023",

month = mar,

doi = "10.1007/s11523-023-00947-9",

language = "English",

volume = "18",

pages = "311",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Adis",

number = "2",

}

Popat, S, Ahn, MJ, Ekman, S, Leighl, NB, Ramalingam, SS, Reungwetwattana, T, Siva, S, Tsuboi, M, Wu, YL & Yang, JCH 2023, 'Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)', Targeted Oncology, vol. 18, no. 2, pp. 311. https://doi.org/10.1007/s11523-023-00947-9

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7). / Popat, Sanjay; Ahn, Myung Ju; Ekman, Simon et al.
In: Targeted Oncology, Vol. 18, No. 2, 03.2023, p. 311.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)

AU - Popat, Sanjay

AU - Ahn, Myung Ju

AU - Ekman, Simon

AU - Leighl, Natasha B.

AU - Ramalingam, Suresh S.

AU - Reungwetwattana, Thanyanan

AU - Siva, Shankar

AU - Tsuboi, Masahiro

AU - Wu, Yi Long

AU - Yang, James Chih Hsin

PY - 2023/3

Y1 - 2023/3

N2 - While typesetting the articles the formatting of the Tables was incorrect. Now this has been corrected. The original article has been corrected.

AB - While typesetting the articles the formatting of the Tables was incorrect. Now this has been corrected. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85147676259

U2 - 10.1007/s11523-023-00947-9

DO - 10.1007/s11523-023-00947-9

M3 - Comment/debate

C2 - 36752975

AN - SCOPUS:85147676259

SN - 1776-2596

VL - 18

SP - 311

JO - Targeted Oncology

JF - Targeted Oncology

IS - 2

ER -

Popat S, Ahn MJ, Ekman S, Leighl NB, Ramalingam SS, Reungwetwattana T et al. Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7). Targeted Oncology. 2023 Mar;18(2):311. doi: 10.1007/s11523-023-00947-9

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this